Béla Merkely

6 ta ish

Semmelweis University

1. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

   Frank L.J. Visseren, François Mach, Yvo M. Smulders +97

   MaqolaOAOchiq kirish20219 iqtibos

   ABIABI:AkademIndex/2026.other.057806

2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

   Milton Packer, Stefan D. Anker, Javed Butler +36

   Maqola20208 iqtibos

   ABIABI:AkademIndex/2026.other.282518

3. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

   Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres +88

   Maqola20207 iqtibos

   ABIABI:AkademIndex/2026.other.442171

4. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

   John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35

   Maqola20196 iqtibos

   ABIABI:AkademIndex/2026.other.282514

5. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

   Scott D. Solomon, John J.V. McMurray, Inder S. Anand +31

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295865

6. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

   Scott D. Solomon, Muthiah Vaduganathan, Brian Claggett +22

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.295867